Browsing Tag
New Enterprise Associates
9 posts
Positron AI valuation jumps fourfold to $5bn as Liberty Global joins $875m funding round
Liberty Global backs Positron AI in an $875 million round valuing the Nvidia challenger at $5 billion as AI inference demand accelerates.
Positron AI lands $875m to fund Asimov inference chip production
Positron AI has secured $875 million at a $5 billion post-money valuation after deploying more than 50 Atlas racks at Oracle Cloud Infrastructure, but its custom Asimov silicon will not reach production until the second half of 2027.
UK-backed CuspAI targets semiconductor and energy bottlenecks with $450m round
CuspAI has secured $450 million at a $2.6 billion valuation to connect artificial intelligence, laboratories and manufacturers, but commercial value depends on turning digital candidates into validated materials.
TwelveLabs rakes in $100m as video AI moves toward enterprise intelligence
TwelveLabs has raised $100 million to expand its video-native artificial intelligence platform, deepen its Amazon Web Services alliance and move from video search models into enterprise applications.
Anterior raises $40m to scale payer workflow automation as healthcare AI shifts from pilots to production
Anterior Inc. secures $40 million to expand health plan AI deployment. Discover what this signals for payer automation, investors, and the future of healthcare workflows.
Coursera (NYSE: COUR) and Udemy (NASDAQ: UDMY) to combine as skills race accelerates
Coursera is merging with Udemy in a $2.5B deal to reshape AI-driven learning. Find out what this means for skills, platforms, and enterprise training.
Tagworks Pharmaceuticals bags $65m in Series A for Click-to-Release technology
Tagworks Pharmaceuticals BV, a Netherlands-based pioneer in Click-to-Release chemistry that promotes more effective and safer systemic therapies, has…
Precision oncology company Black Diamond Therapeutics raises $85m
Black Diamond Therapeutics, a precision oncology company based in Cambridge, has raised $85 million from a Series C…
Mirum Pharmaceuticals raises $120m to advance Maralixibat for rare liver diseases
Mirum Pharmaceuticals, a clinical-stage pharmaceutical company, has successfully raised $120 million in a Series A funding round to…